His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology. With extensive experience in Clinical Development, International Medical Affairs, and Pharmacovigilance, he has played a key role in the development and commercialization of pharmaceuticals across multiple therapeutic areas globally, including successful medicines such as Advair, Xarelto, and Eylea.

Recently, Dr Devoy has led the creation of the Bayer Bioethics Council, an independent external body providing ethical expertise and educational support to Bayer with regards to bioethics matters in the context of R&D-related innovation in life sciences, with a focus on medical topics, bioengineering and artificial intelligence, and which may concern the discovery, development, manufacturing, and use of human health directed treatments and therapies as well as agricultural products and practices for implementation.

Dr. Devoy is particularly passionate about sustainable ageing, the impact of longevity on society and transforming healthcare to support healthy, active lifestyles as people age, as well as advancing medical science and improving patient outcomes through innovation, collaboration, and excellence.